江苏蓝丰生物化工股份有限公司2025年度利润分配预案详细解读
江苏蓝丰生物化工股份有限公司2025年度利润分配预案详细解读
主要内容摘要
- 公司2025年度亏损严重，归属于上市公司股东的净利润为-1.91亿元，累计未分配利润为-26.43亿元。
- 2025年度不派发现金红利、不送红股、不以资本公积转增股本。
- 董事会认为利润分配预案符合公司实际情况和法规要求，有利于公司持续健康发展。
- 该预案尚需提交股东大会审议。
详细内容分析
江苏蓝丰生物化工股份有限公司（证券代码：002513，以下简称“公司”）于2026年4月16日召开第七届董事会第三十三次会议，审议并通过了《关于公司2025年度利润分配预案的议案》。此次利润分配预案尚需提交公司2025年年度股东大会审议。
财务数据与利润分配情况
- 2025年度业绩：
- 经公证天业会计师事务所审计，公司2025年度实现归属于上市公司股东的净利润为-19,052.53万元（约-1.91亿元）。
- 2025年末公司合并报表累计未分配利润为-264,302.26万元（约-26.43亿元）。
- 资本公积余额为233,920.03万元（约23.39亿元）。
- 母公司累计未分配利润为-235,010.84万元（约-23.50亿元）。
- 近三年分红情况：
- 2023、2024、2025三个会计年度，公司均未进行现金分红、未送红股、未以资本公积转增股本，现金分红及回购注销总额均为0。
- 近三年平均净利润为-25,842.89万元（约-2.58亿元）。
2025年度利润分配预案
鉴于公司2025年度及期末累计未分配利润均为负数，不符合《公司法》、《深圳证券交易所股票上市规则》、《公司章程》等有关利润分配的条件，公司拟定2025年度不派发现金红利、不送红股、不以资本公积转增股本。公司强调，此举是基于经营业绩、资金状况、保障正常生产经营和项目建设等资金需求及公司长远发展战略的综合考虑，目的是为公司持续发展和投资者长期回报提供保障。
对股东的影响及风险提示
- 不分红的原因： 公司2025年度发生亏损，且累计可供分配利润为负数，无法进行利润分配。
- 合规性说明： 公司2025年度利润分配预案不触及深圳证券交易所《股票上市规则》中关于实施其他风险警示的规定。
- 潜在影响： 连续多年未分红且业绩持续亏损，可能会对投资者信心及公司股价产生负面影响，尤其是对于追求分红收益的投资者而言，这可能成为短期内股价承压的负面因素。
- 决议流程： 本次利润分配预案已由董事会审议通过，后续还需提交年度股东大会审议通过方可最终实施。
董事会意见
董事会认为，2025年度利润分配预案与公司当前经营业绩、未来发展规划相匹配，符合公司实际情况和相关法律法规规定，有利于公司持续、稳定、健康发展，不存在损害公司及全体股东、尤其是中小股东利益的情况。
备查文件
结论
投资者需要重点关注： 公司已连续多年亏损且未进行分红，2025年度也确定不分红。公司亏损及未分红情况可能会对股价及投资者信心产生直接影响。建议投资者密切关注公司后续业绩改善及资金状况变化，并关注年度股东大会的最终决议。
免责声明：本文仅供投资者参考，不构成任何投资建议。投资有风险，决策需谨慎。
English Version
Detailed Analysis of Jiangsu LanFeng Biochemical Co., Ltd. 2025 Profit Distribution Plan
Detailed Analysis of Jiangsu LanFeng Biochemical Co., Ltd. 2025 Profit Distribution Plan
Key Highlights
- Significant loss in 2025: Net profit attributable to shareholders is -191 million RMB, with accumulated undistributed profit at -2.643 billion RMB.
- No cash dividend, no bonus shares, and no conversion of capital reserve into share capital for 2025.
- The Board believes the profit distribution plan matches the company’s situation and legal requirements, supporting long-term development.
- The proposal still needs approval at the Annual General Meeting of Shareholders.
Detailed Analysis
Jiangsu LanFeng Biochemical Co., Ltd. (stock code: 002513, “the Company”) held its 33rd Board Meeting of the 7th session on April 16, 2026, and approved the “2025 Annual Profit Distribution Proposal.” This proposal is pending approval at the 2025 Annual General Meeting of Shareholders.
Financial Data and Profit Distribution
- 2025 Performance:
- Audited by Gongzheng Tianye CPA, the company achieved a net profit attributable to shareholders of -191 million RMB in 2025.
- As of year-end 2025, the consolidated accumulated undistributed profit was -2.643 billion RMB.
- Capital reserve stood at 2.339 billion RMB.
- Parent company’s accumulated undistributed profit was -2.350 billion RMB.
- Dividend History (past three years):
- No cash dividends, bonus shares, or capital reserve to share capital in 2023, 2024, or 2025; both dividend and share repurchase totals were zero.
- Average net profit for the last three years was -258 million RMB.
2025 Profit Distribution Plan
Since both the 2025 annual and accumulated undistributed profits are negative, the company does not meet the legal requirements for profit distribution as per the Company Law, Shenzhen Stock Exchange rules, and company bylaws. Thus, for 2025, there will be no cash dividend, no bonus shares, and no capital reserve conversion. The company stresses this is a strategic move to safeguard operations, maintain liquidity for ongoing projects and development, and support long-term growth and investor returns.
Impact on Shareholders and Risk Reminder
- Reason for No Dividend: The company incurred losses in 2025 and has negative accumulated distributable profit, making profit distribution impossible.
- Compliance: The 2025 profit distribution plan does not trigger other risk warnings as per Shenzhen Stock Exchange rules.
- Potential Impact: The sustained losses and ongoing absence of dividends may negatively affect investor confidence and share price, especially for those seeking dividend returns.
- Approval Process: The plan has been approved by the Board and awaits final shareholder meeting approval.
Board Opinion
The Board states the plan fits the company’s performance and future planning, complies with all laws and regulations, and does not harm the interests of shareholders, especially minority shareholders.
Supporting Documents
- Resolutions from the 33rd meeting of the 7th Board of Directors.
Conclusion
Investor Focus: The company has been loss-making for several years with no dividends, and 2025 continues this trend. This situation may pressure the share price and investor confidence. Investors should monitor future earnings improvement and the outcome of the annual shareholders’ meeting closely.
Disclaimer: This article is for reference only and does not constitute investment advice. Investments involve risks. Please make decisions prudently.
View 蓝丰生化 Historical chart here
